EXPERIENCE WITH CEFPIRAMIDE (SM-1652) IN RESPIRATORY TRACT INFECTION AND ITS SERUM CONCENTRATION AFTER CONTINUOUS USAGE

Patients with infections of the respiratory tract were treated in a clinical trial of cefpiramide (CPM, SM-1652), a new antibiotic, to assess its efficacy and accumulation rate after 14 days usage. Of 14 patients receiving cefpiramide alone, 935 responded with significant clinical improvements. Feve...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 31; no. Supplement1; pp. 436 - 440
Main Authors SHIGEMATU, NOBUAKI, OGUSHI, OSAMU, HIGUCHI, KAZUYUKI, NINOMIYA, KIYOSHI, MIYAZAKI, NOBUYOSHI
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 30.05.1983
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.31.Supplement1_436

Cover

More Information
Summary:Patients with infections of the respiratory tract were treated in a clinical trial of cefpiramide (CPM, SM-1652), a new antibiotic, to assess its efficacy and accumulation rate after 14 days usage. Of 14 patients receiving cefpiramide alone, 935 responded with significant clinical improvements. Fever was occurred in 3 cases and eruption was occurred in one case. A slight elevation of serum transaminases occurred in 3 cases during the cefpiramide therapy, returned normal levels soon after the withdrawal of the drug without any treatment. The difference of the serum concentration between the initial administration and 14 days of the drug revealed no remarkable changes suggesting that there is no accumulative nature in the drug.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.31.Supplement1_436